Diagnosis and management of nasal and pharyngeal dendritic cell tumor-case report and literature review / 临床耳鼻咽喉头颈外科杂志

OBJECTIVE@#To investigate the clinical manifestation, pathological characteristics, treatment and prognosis of dendritic cell tumor.@*METHOD@#Four cases of nasal and pharyngeal dendritic cell tumor were described, including two cases of follicular dendritic cell sarcoma (FDCS), one case of Langerhans cell histiocytosis (LCH) and one case of Langer hans cell sarcoma (LCS). One of the patients with FDCS received multimodality therapy (surgery combined with chemotherapy), and the other patient only received chemotherapy and radiotherapy. The patients with LCH or LSC were treated by surgery.@*RESULT@#Of the two FDCS patients, one achieved complete remission after treatment by surgery combined with four cycles of CHOP chemotherapy regimen and concurrent radiotherapy (50 Gy), and the other who only received chemotherapy and radiotherapy survived with tumor for more than seven months of follow up. The patient of LCH was followed up for more than 2 years after surgery without recurrence or metastasis. The patient of LCS did not undergo radiotherapy or chemotherapy after surgery and died after 10 months of follow up.@*CONCLUSION@#Dendritic cell tumor is a group of very rare tumor and can be easily misdiagnosed in clinic, the confirmed diagnosis of which relies on histopathological features, immunohistochemistry combined with electron microscopy. FDCS, LCH and LCS have different pathological features, immunophenotypes and prognosis.

Clinical analysis and review of 8 cases with sinonasal neuroendocrine carcinoma / 临床耳鼻咽喉头颈外科杂志

OBJECTIVE@#To study the diagnosis, treatment and prognosis of sinonasal neuroendocrine carcinoma.@*METHOD@#Eight patients with sinonasal neuroendocrine carcinoma from February 2009 to February 2012 were retrospectively analyzed and the related literatures were reviewed.@*RESULT@#There were seven males and one female. Three cases were treated by surgery only, one case received surgery followed by radiotherapy, and four cases were treated by combined treatment (surgery followed by radiotherapy and chemotherapy). There were three patients with a primary tumor originating from the maxillary sinus, two cases died after 8 and 14 months, another patient was survived in 10 months of follow-up, and the carcinomas did not recur. There were five patients with primary neuroendocrine carcinoma from the nasal cavity, one patient recurred after the surgery and after radiotherapy, the patient did not recur after 20 months of follow-up, and the other four patients did not recur, in 13, 20, 27 and 28 months of follow-up.@*CONCLUSION@#Neuroendocrine carcinomas of the sinuses are rare malignant tumors. Neuroendocrine carcinomas cases with the lesions at different sites differ in the clinical manifestations and prognosis, pathology, immunocytochemistry and electron microscopy, It should be differentiated from poorly differentiated squamous carcinoma melanoma, olfactory nerve blastoma and neurospongioma. The key to improve the survival rate of the disease is early accurate diagnosis and combined treatment.

The clinical study of eight cases of nasal solitary keratoacanthoma / 临床耳鼻咽喉头颈外科杂志

The clinical and pathological data of eight cases of nasal solitary keratoacanthoma were analyzed and relevant literatures were reviewed. All of the cases were verified via pathological examination after local lesion excision, along with reconstruction of tissue defects in external nose. The patients were all primary healed. With a follow up from 8 months up to 7 years, only one case relapsed one year after first surgery, and given another operation, no recurrence happened thereafter. The other seven cases did not recur so far. The nasal solitary keratoacanthoma is a squamous tumor with potential malignancy, which manifests similarly with squamous cell carcinoma, and the correct diagnosis requires comprehensive judgment from both the clinical and histopathological characteristics. The disease shows favorable prognosis and low recurrence rate.